Salvage lenalidomide in four rare oncological diseases

Area of Science:

• Hematology
• Oncology
• Rare Diseases

Background:

• Standard therapy recommendations are often lacking for rare, aggressive, and relapsing diseases.
• Patients with refractory conditions may benefit from novel, experimental treatment approaches.

Observation:

• A cohort of four adult patients with aggressive, multisystem, and relapsing rare diseases were treated with lenalidomide.
• Lenalidomide was administered as second- to fourth-line treatment (10-25 mg daily on days 1-21 of a 28-day cycle).

Findings:

• Complete and durable remissions (over 1 year, no maintenance) were observed in Langerhans cell histiocytosis (with dexamethasone, etoposide, and stem cell transplant) and plasma-cell Castleman disease (monotherapy).
• A mixed response, including complete resolution of brain lesions, was seen in Erdheim-Chester disease (monotherapy).
• Gastrointestinal bleeding was effectively managed in multiple angiomatosis (with thalidomide).

Implications:

• Lenalidomide demonstrates significant therapeutic potential in managing various rare, aggressive hematologic and systemic diseases.
• This study highlights lenalidomide as a viable treatment option for refractory cases where standard therapies are ineffective.
• Further research into lenalidomide-based regimens for rare diseases is warranted to establish its efficacy and safety profile.